Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $980992.0.

  • Collegium Pharmaceutical's Gains from Sales and Divestitures rose 431.9% to $980992.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $980992.0, marking a year-over-year increase of 431.9%. This contributed to the annual value of $967773.0 for FY2024, which is 4323.65% up from last year.
  • Per Collegium Pharmaceutical's latest filing, its Gains from Sales and Divestitures stood at $980992.0 for Q3 2025, which was up 431.9% from $895705.0 recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Gains from Sales and Divestitures peaked at $980992.0 during Q3 2025, and registered a low of $352548.0 during Q1 2021.
  • In the last 5 years, Collegium Pharmaceutical's Gains from Sales and Divestitures had a median value of $626539.0 in 2023 and averaged $654488.0.
  • As far as peak fluctuations go, Collegium Pharmaceutical's Gains from Sales and Divestitures surged by 8053.46% in 2021, and later surged by 196.46% in 2025.
  • Collegium Pharmaceutical's Gains from Sales and Divestitures (Quarter) stood at $444769.0 in 2021, then increased by 28.88% to $573204.0 in 2022, then grew by 17.87% to $675647.0 in 2023, then skyrocketed by 43.24% to $967773.0 in 2024, then grew by 1.37% to $980992.0 in 2025.
  • Its Gains from Sales and Divestitures was $980992.0 in Q3 2025, compared to $895705.0 in Q2 2025 and $792945.0 in Q1 2025.